Analysis of safety reporting requirements during medical device clinical trials in Japan

Kentaro Azuma, Hiroshi Iseki

    Research output: Contribution to journalArticle

    3 Citations (Scopus)

    Abstract

    Regulatory convergence in safety reporting requirements for medical device clinical trials has not yet been achieved. The Global Harmonization Task Force (GHTF) issued new guidance, GHTF/SG5/N5, on this topic in August 2012. First, we compared current reporting requirements for drug and medical devices in Japan with the international guidelines International Conference on Harmonization (ICH)-E2A/E2F and GHTF/SG5/N5. As a result, we confirmed that Japan's expedited reporting requirements are nearly the same for drugs and medical devices and that these requirements are similar to those described in ICH-E2A. We also found that GHTF/SG5/N5 differs from the ICH-E2A in several ways. We sorted these differences into three categories: reportable events, reporting time frame, and definitions of terms. Although there are several equivalent terms between the ICH and GHTF guidelines, the terms Serious Health Threat and Device Deficiency are only defined in GHTF/SG5/N5. The reporting time frame for a Serious Adverse Event is either 10 or 30 days for medical devices; expedited reporting is not required according to ICH-E2A, but it is covered in the annual Development Safety Update Report in ICH-E2F. GHTF/SG5/N5 recommends substantially stricter requirements than the current requirements in Japan. Therefore, the Ministry of Health, Labour and Welfare (MHLW) seemed to have prioritized the introduction of consistent definitions of terms while maintaining the current reporting time frame, rather than introducing GHTF guidance as it is. This policy is in accordance with the draft proposal on the revision of safety reporting requirements issued by MHLW in October 2012.

    Original languageEnglish
    Pages (from-to)234-241
    Number of pages8
    JournalJournal of Artificial Organs
    Volume16
    Issue number2
    DOIs
    Publication statusPublished - 2013 Jun

    Fingerprint

    Advisory Committees
    Japan
    Health
    Clinical Trials
    Safety
    Equipment and Supplies
    Personnel
    Pharmaceutical Preparations
    Guidelines

    Keywords

    • Adverse event
    • Clinical trial
    • Global Harmonization Task Force
    • Medical device
    • Regulatory

    ASJC Scopus subject areas

    • Biomaterials
    • Biomedical Engineering
    • Cardiology and Cardiovascular Medicine
    • Medicine (miscellaneous)

    Cite this

    Analysis of safety reporting requirements during medical device clinical trials in Japan. / Azuma, Kentaro; Iseki, Hiroshi.

    In: Journal of Artificial Organs, Vol. 16, No. 2, 06.2013, p. 234-241.

    Research output: Contribution to journalArticle

    Azuma, Kentaro ; Iseki, Hiroshi. / Analysis of safety reporting requirements during medical device clinical trials in Japan. In: Journal of Artificial Organs. 2013 ; Vol. 16, No. 2. pp. 234-241.
    @article{6b05eb9c52a84e43bf01ffb19763cf3b,
    title = "Analysis of safety reporting requirements during medical device clinical trials in Japan",
    abstract = "Regulatory convergence in safety reporting requirements for medical device clinical trials has not yet been achieved. The Global Harmonization Task Force (GHTF) issued new guidance, GHTF/SG5/N5, on this topic in August 2012. First, we compared current reporting requirements for drug and medical devices in Japan with the international guidelines International Conference on Harmonization (ICH)-E2A/E2F and GHTF/SG5/N5. As a result, we confirmed that Japan's expedited reporting requirements are nearly the same for drugs and medical devices and that these requirements are similar to those described in ICH-E2A. We also found that GHTF/SG5/N5 differs from the ICH-E2A in several ways. We sorted these differences into three categories: reportable events, reporting time frame, and definitions of terms. Although there are several equivalent terms between the ICH and GHTF guidelines, the terms Serious Health Threat and Device Deficiency are only defined in GHTF/SG5/N5. The reporting time frame for a Serious Adverse Event is either 10 or 30 days for medical devices; expedited reporting is not required according to ICH-E2A, but it is covered in the annual Development Safety Update Report in ICH-E2F. GHTF/SG5/N5 recommends substantially stricter requirements than the current requirements in Japan. Therefore, the Ministry of Health, Labour and Welfare (MHLW) seemed to have prioritized the introduction of consistent definitions of terms while maintaining the current reporting time frame, rather than introducing GHTF guidance as it is. This policy is in accordance with the draft proposal on the revision of safety reporting requirements issued by MHLW in October 2012.",
    keywords = "Adverse event, Clinical trial, Global Harmonization Task Force, Medical device, Regulatory",
    author = "Kentaro Azuma and Hiroshi Iseki",
    year = "2013",
    month = "6",
    doi = "10.1007/s10047-013-0692-6",
    language = "English",
    volume = "16",
    pages = "234--241",
    journal = "Journal of Artificial Organs",
    issn = "1434-7229",
    publisher = "Springer Japan",
    number = "2",

    }

    TY - JOUR

    T1 - Analysis of safety reporting requirements during medical device clinical trials in Japan

    AU - Azuma, Kentaro

    AU - Iseki, Hiroshi

    PY - 2013/6

    Y1 - 2013/6

    N2 - Regulatory convergence in safety reporting requirements for medical device clinical trials has not yet been achieved. The Global Harmonization Task Force (GHTF) issued new guidance, GHTF/SG5/N5, on this topic in August 2012. First, we compared current reporting requirements for drug and medical devices in Japan with the international guidelines International Conference on Harmonization (ICH)-E2A/E2F and GHTF/SG5/N5. As a result, we confirmed that Japan's expedited reporting requirements are nearly the same for drugs and medical devices and that these requirements are similar to those described in ICH-E2A. We also found that GHTF/SG5/N5 differs from the ICH-E2A in several ways. We sorted these differences into three categories: reportable events, reporting time frame, and definitions of terms. Although there are several equivalent terms between the ICH and GHTF guidelines, the terms Serious Health Threat and Device Deficiency are only defined in GHTF/SG5/N5. The reporting time frame for a Serious Adverse Event is either 10 or 30 days for medical devices; expedited reporting is not required according to ICH-E2A, but it is covered in the annual Development Safety Update Report in ICH-E2F. GHTF/SG5/N5 recommends substantially stricter requirements than the current requirements in Japan. Therefore, the Ministry of Health, Labour and Welfare (MHLW) seemed to have prioritized the introduction of consistent definitions of terms while maintaining the current reporting time frame, rather than introducing GHTF guidance as it is. This policy is in accordance with the draft proposal on the revision of safety reporting requirements issued by MHLW in October 2012.

    AB - Regulatory convergence in safety reporting requirements for medical device clinical trials has not yet been achieved. The Global Harmonization Task Force (GHTF) issued new guidance, GHTF/SG5/N5, on this topic in August 2012. First, we compared current reporting requirements for drug and medical devices in Japan with the international guidelines International Conference on Harmonization (ICH)-E2A/E2F and GHTF/SG5/N5. As a result, we confirmed that Japan's expedited reporting requirements are nearly the same for drugs and medical devices and that these requirements are similar to those described in ICH-E2A. We also found that GHTF/SG5/N5 differs from the ICH-E2A in several ways. We sorted these differences into three categories: reportable events, reporting time frame, and definitions of terms. Although there are several equivalent terms between the ICH and GHTF guidelines, the terms Serious Health Threat and Device Deficiency are only defined in GHTF/SG5/N5. The reporting time frame for a Serious Adverse Event is either 10 or 30 days for medical devices; expedited reporting is not required according to ICH-E2A, but it is covered in the annual Development Safety Update Report in ICH-E2F. GHTF/SG5/N5 recommends substantially stricter requirements than the current requirements in Japan. Therefore, the Ministry of Health, Labour and Welfare (MHLW) seemed to have prioritized the introduction of consistent definitions of terms while maintaining the current reporting time frame, rather than introducing GHTF guidance as it is. This policy is in accordance with the draft proposal on the revision of safety reporting requirements issued by MHLW in October 2012.

    KW - Adverse event

    KW - Clinical trial

    KW - Global Harmonization Task Force

    KW - Medical device

    KW - Regulatory

    UR - http://www.scopus.com/inward/record.url?scp=84879412372&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84879412372&partnerID=8YFLogxK

    U2 - 10.1007/s10047-013-0692-6

    DO - 10.1007/s10047-013-0692-6

    M3 - Article

    VL - 16

    SP - 234

    EP - 241

    JO - Journal of Artificial Organs

    JF - Journal of Artificial Organs

    SN - 1434-7229

    IS - 2

    ER -